The CERO 3D showcases the ability to continuously produce functional CAR-macrophages at scale. These CAR-macrophages demonstrated enhanced anti-cancer activity, highlighting the potential of CERO 3D for advancing the development of effective cell-based immunotherapies.

Representative fluorescent microscopic images of the different steps of the hematopoietic differentiation of hiPSCs to iMacs.”

Reference: M. Abdin et. al. (2023) Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia, J Immunother Cancer. 2023; 11(12): e007705

The CERO 3D is capable to generate functionally relevant macrophages from iPSC-derived hematopoietic organoids. This innovative, xeno-free approach enables the efficient and continuous production of macrophages, providing a valuable model for immunomodulatory drug testing.

Reference: Ackermann et. al. (2024) Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions, Stem Cell Res Ther. 2024; 15: 171